Finorify

MRNA

Moderna, Inc.

$137.99-0.25%

Price

MRNA daily closing price
Market cap
$55.06 billion
52W range
$22.36 – $174.38
Volume
17.7M
Sector
Healthcare

Moderna, Inc. (MRNA) last closed at $137.99, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for MRNA, covered for search and blurred for visitors.

Performance

  • 1D+1.54%
  • 5D+8.62%
  • 1M+34.65%
  • 3M+331.09%
  • 6M+342.10%
  • 1Y+802.39%
  • 5Y-23.54%

Financials

MRNA revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, Moderna, Inc. reported revenue of $2.23 billion.

The prior window totaled $3.08 billion, so the latest window is lower than that stretch.

Operating cash flow in the latest window was -$2 billion.

Free cash flow in the latest window was -$2.13 billion.

These amounts are taken from Moderna, Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE -11.6% (0 of 100). Leverage: D/E 0.09× (97 of 100). Cash generation: FCF margin -95.8% (0 of 100). Net margin: -539.3% (0 of 100). Liquidity: Current 2.29× (100 of 100).

Finorify's notes from those filings, written September 25, 2026: Proprietary, Modular mRNA Platform. Moderna's core mRNA platform enables rapid design, testing, and production of candidates by treating genetic instructions as digital code. This modular technology allows scientific and manufacturing learnings from one program (e.g., respiratory vaccines) to be applied across a broad spectrum of therapeutic areas, including oncology and rare diseases, significantly reducing discovery timelines. Advanced Delivery Systems and Deep IP Estate. The company has developed proprietary lipid nanoparticle (LNP) formulations and chemical modifications that optimize mRNA stability, cellular uptake, and immune response while minimizing toxicity. Its extensive portfolio of patents covering these delivery mechanisms and engineered mRNA constructs creates a substantial barrier to entry for potential competitors. Digitally Integrated, Scalable Manufacturing Infrastructure. Moderna has built custom, highly automated manufacturing facilities capable of switching between different mRNA molecules quickly. This dedicated infrastructure allows the company to rapidly transition candidates from digital sequence design to clinical and commercial-grade batch production at scale, supporting both pandemic response and multi-product commercialization. Respiratory Product Concentration and Seasonal Demand Volatility. Moderna remains heavily reliant on commercial revenues from its respiratory vaccine portfolio (such as COVID-19 and RSV vaccines). Demand in these endemic and seasonal markets is subject to consumer fatigue, fluctuating vaccination rates, and fierce competition from established pharmaceutical giants. High R&D Burn and Clinical Trial Attrition. Expanding beyond respiratory vaccines into individualized neoantigen therapies, latent virus vaccines, and rare disease therapeutics requires massive research and development expenditures. The risk of clinical trial failures, regulatory delays, or lack of commercial adoption poses a material threat to profitability and cash reserves. Intellectual Property Litigation and Licensing Exposure. The mRNA and lipid nanoparticle landscape is heavily contested. Ongoing and potential patent infringement lawsuits from third parties pose risks of substantial damages, royalties, or licensing burdens that could compress gross margins or restrict freedom to operate.

Cash Flow

MRNA free cash flowQ3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Margins

MRNA operating margin

Valuation

P/S (TTM)
24.71

Insights

Advantage

Proprietary, Modular mRNA Platform

Moderna's core mRNA platform enables rapid design, testing, and production of candidates by treating genetic instructions as digital code. This modular technology allows scientific and manufacturing learnings from one program (e.g., respiratory vaccines) to be applied across a broad spectrum of therapeutic areas, including oncology and rare diseases, significantly reducing discovery timelines.

Advantage

Advanced Delivery Systems and Deep IP Estate

The company has developed proprietary lipid nanoparticle (LNP) formulations and chemical modifications that optimize mRNA stability, cellular uptake, and immune response while minimizing toxicity. Its extensive portfolio of patents covering these delivery mechanisms and engineered mRNA constructs creates a substantial barrier to entry for potential competitors.

Advantage

Digitally Integrated, Scalable Manufacturing Infrastructure

Moderna has built custom, highly automated manufacturing facilities capable of switching between different mRNA molecules quickly. This dedicated infrastructure allows the company to rapidly transition candidates from digital sequence design to clinical and commercial-grade batch production at scale, supporting both pandemic response and multi-product commercialization.

Risk

Respiratory Product Concentration and Seasonal Demand Volatility

Moderna remains heavily reliant on commercial revenues from its respiratory vaccine portfolio (such as COVID-19 and RSV vaccines). Demand in these endemic and seasonal markets is subject to consumer fatigue, fluctuating vaccination rates, and fierce competition from established pharmaceutical giants.

Risk

High R&D Burn and Clinical Trial Attrition

Expanding beyond respiratory vaccines into individualized neoantigen therapies, latent virus vaccines, and rare disease therapeutics requires massive research and development expenditures. The risk of clinical trial failures, regulatory delays, or lack of commercial adoption poses a material threat to profitability and cash reserves.

Risk

Intellectual Property Litigation and Licensing Exposure

The mRNA and lipid nanoparticle landscape is heavily contested. Ongoing and potential patent infringement lawsuits from third parties pose risks of substantial damages, royalties, or licensing burdens that could compress gross margins or restrict freedom to operate.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open MRNA in Finorify